(Press-News.org) People tend to perceive their dominant hand as staying relatively the same size even when it's magnified, lending support to the idea that we use our hand as a constant perceptual "ruler" to measure the world around us. The findings are published in Psychological Science, a journal of the Association for Psychological Science.
"These findings suggest that our bodies are used as perceptual metrics, meaning that we are more likely to attribute changes in the perceived size of the hand to changes in the world — instead of thinking that our hand has become bigger, we're more likely to think that the world around the hand has become smaller instead," explains psychological scientist and lead researcher Sally Linkenauger of Lancaster University.
To size up the world around us, we need to be able to translate the information that comes in through our eyes into units that are relevant to our everyday lives. The body is a particularly effective metric because it allows us to relate information about object size to actions that we're able to perform on or with the object.
Linkenauger and colleagues hypothesized that the dominant hand might be the most useful metric for objects of commensurate size because it is one of our primary means of interacting with our environment, through both touch and grasp. Using magnification, the researchers conducted several experiments to test whether the dominant hand is used as a constant, reliable metric.
Across five experiments, participants viewed their dominant hand, as well as various other items, under 18% magnification. Results showed that the participants consistently estimated their dominant hand to be significantly less magnified than the other items, which included their non-dominant hand, their foot, an experimenter's hand and foot, and a pen.
"In most cases, individuals knew that their dominant hand was under the same degree of magnification as another's hands, feet, and objects, yet they persisted to report that what they experience was a smaller degree of magnification for their dominant hand," says Linkenauger. "Individuals typically like to be consistent and 'right,' but this effect seemed to override those affectations."
According to Linkenauger, the research may have implications for certain neurological conditions and physical rehabilitation. The research may even have implications for human-computer interfaces, and Linkenauger hopes to investigate whether hand size constancy also applies to virtual environments in which individuals have an animated virtual hand.
INFORMATION:
In addition to Linkenauger, co-authors include Michael N. Geuss and Jeanine K. Stefanucci (Utah University), Markus Leyrer and Betty J. Mohler (Max Planck Institute for Biological Cybernetics), Beth H. Richardson (University of Central Lancaster), Heinrich H. Bulthoff (Max Planck Institute for Biological Cybernetics and Korea University), and Dennis R. Proffitt (University of Virginia).
Part of H.H. Bulthoff's research was supported by the Brain Korea 21 PLUS Program through the National Research Foundation of Korea, funded by the Ministry of Education. S.A. Linkenauger's research was supported by the Alexander von Humboldt Foundation.
For more information about this study, please contact: Sally Linkenauger at s.linkenauger@lancaster.ac.uk.
The article abstract is available online: http://pss.sagepub.com/content/early/2014/09/22/0956797614548875.abstract
The APS journal Psychological Science is the highest ranked empirical journal in psychology. For a copy of the article "Evidence for Hand-Size Constancy: The Dominant Hand as a Natural Perceptual Metric" and access to other Psychological Science research findings, please contact Anna Mikulak at 202-293-9300 or amikulak@psychologicalscience.org.
Hand size appears to stay constant, providing natural 'ruler'
2014-09-29
ELSE PRESS RELEASES FROM THIS DATE:
More children admitted to intensive care but with lower staffing ratios
2014-09-29
More children than ever are being admitted to intensive care units in England and Wales but there are fewer staff per bed available to cope with the increase, according to a new report published jointly by the University of Leeds and University of Leicester.
The Paediatric Intensive Care Audit Network (PICANet) report showed that there was a 15% increase in admissions over a 10-year period between 2004 and 2013, but this included an increase of 4% that was not due to changes in the childhood population.
At the same time, staffing levels have increased by 36% but this ...
Researchers identify early sign of pancreatic cancer
2014-09-28
BOSTON –– Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. The research is being published online today by the journal Nature Medicine.
Although the increase isn't large enough to be the basis of a new test for early detection of the disease, the findings will help researchers better understand how pancreatic cancer affects the rest of the body, ...
Human genome was shaped by an evolutionary arms race with itself
2014-09-28
New findings by scientists at the University of California, Santa Cruz, suggest that an evolutionary arms race between rival elements within the genomes of primates drove the evolution of complex regulatory networks that orchestrate the activity of genes in every cell of our bodies.
The arms race is between mobile DNA sequences known as "retrotransposons" (a.k.a. "jumping genes") and the genes that have evolved to control them. The UC Santa Cruz researchers have, for the first time, identified genes in humans that make repressor proteins to shut down specific jumping ...
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
2014-09-27
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea.
"We wanted ...
Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
2014-09-27
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid.
In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment with the combination of pemetrexed and cisplatin than those whose tumours expressed high levels.
"Thymidylate synthase is one of the proteins that is targeted by pemetrexed which ...
French studies measure benefits of colorectal cancer screening
2014-09-27
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.
Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976. They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began ...
Crizotinib treatment effective against ROS1-positive lung cancer
2014-09-27
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.
"Prior to this study, there were a handful of reports describing marked responses to crizotinib ...
Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show
2014-09-27
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.
"When chemotherapy is administered after the first trimester of pregnancy, we cannot discern any problems in the children," says lead author Dr Frederic Amant, KU Leuven and University Hospitals Leuven in Belgium. "Fear about the risks of chemotherapy administration should not be a reason to terminate a pregnancy, delay cancer treatment for the mother, or ...
Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia
2014-09-27
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
"Anorexia and cachexia are among the most troubling and distressing symptoms of advanced cancer, for both patients and their families," says the study's principal investigator, Dr Jennifer Temel from the Department of Medicine, Massachusetts General Hospital, Boston, USA.
Symptoms of the wasting syndrome can include a loss of weight and muscles, ...
Afatinib improves progression-free survival in head and neck cancer
2014-09-27
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.
Presented at the ESMO 2014 Congress in Madrid, the Lux-Head & Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median progression-free survival of ...